HMHitoshi Matsuo

Hitoshi Matsuo

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Hitoshi Matsuo has a total of 36 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Prevention of no-reflow/slow-flow phenomenon during rotational atherectomy—A prospective randomized study comparing intracoronary continuous infusion of verapamil and nicorandil

    by Hitoshi Matsuo, Sachiro Watanabe, Takatomo Watanabe, Shunichiro Warita, Tai Kojima, Takeshi Hirose, Makoto Iwama, Koji Ono, Haruki Takahashi, Tomonori Segawa, et al.


    • 1 November 2006
      • Vol. 18  (5) , 843-51

    Genetic factors for obesity.

    by Yoshiji Yamada, Kimihiko Kato, Takashi Kameyama, Kiyoshi Yokoi, Hitoshi Matsuo, Tomonori Segawa, Sachiro Watanabe, Sahoko Ichihara, Hidemi Yoshida, Kei Satoh, et al.

    The purpose of the present study was to identify gene polymorphisms for the reliable assessment of genetic factors for obesity. The study population comprised 3906 unrelated Japanese individuals (2286 men, 1620 women), including 1196 subjects (677 men, 519 women) with obesity (body mass index of > or = 25 kg/m2) and 2710 controls (1609 men, 1101 women). The genotypes for 147 polymorphisms of 124 candidate genes were determined with a method that combines the polymerase chain reaction and sequence-specific oligonucleotide probes with suspension array technology. Multivariable logistic regression analysis with adjustment for age, sex, and the prevalence of smoking revealed that the -30Gright curved arrow A polymorphism of GCK, the -240Aright curved arrow T polymorphism of ACE, and the -482Cright curved arrow T polymorphism of APOC3 were significantly (P < 0.01) associated with the prevalence of obesity, and the -1989Tright curved arrow G polymorphism of ESR1 was almost significantly associated. A stepwise forward selection procedure demonstrated that ACE, GCK, and ESR1 genotypes significantly (P < 0.01) and independently affected the prevalence of obesity. Combined genotype analysis for these three polymorphisms yielded a lowest odds ratio of 0.45 for the combined genotypes of AT or TT for ACE, GG for GCK, and GG for ESR1 in comparison with the combined genotypes of AA for ACE, GG for GCK, and TT or TG for ESR1. Genotypes for ACE, GCK, and ESR1 may prove reliable for the assessment of genetic factors for obesity. Determination of the combined genotypes for these genes may contribute to the personalized prevention of this condition.


  • Open Access

    Genetic factors for obesity

    by Yoshiji Yamada, Kimihiko Kato, Takashi Kameyama, Kiyoshi Yokoi, Hitoshi Matsuo, Tomonori Segawa, Sachiro Watanabe, Sahoko Ichihara, Hidemi Yoshida, Kei Satoh, et al.


    • 1 August 2006
      • Vol. 96  (2) , 220-7

    Assessment of genetic risk for myocardial infarction.

    by Yoshiji Yamada, Hitoshi Matsuo, Tomonori Segawa, Sachiro Watanabe, Kimihiko Kato, Takeshi Hibino, Kiyoshi Yokoi, Sahoko Ichihara, Norifumi Metoki, Hidemi Yoshida, et al.

    Although lifestyle and environmental factors influence the prevalence of myocardial infarction, genetic epidemiological studies have suggested that several genetic variants increase the risk for this condition. We have performed a large-scale association study to identify gene polymorphisms for reliable assessment of the genetic risk of myocardial infarction. The study population comprised 3,483 unrelated Japanese individuals (1,913 men; 1,570 women), including 1,192 subjects with myocardial infarction and 2,291 controls. The genotypes for 164 polymorphisms of 137 candidate genes were determined with an oligonucleotide ligation assay based on analysis of fluorescent microspheres with suspension array technology. Multivariable logistic regression analysis with adjustment for age, sex, body mass index, and the prevalence of smoking, hypertension, diabetes mellitus, and hypercholesterolemia revealed that the 677C-->T (Ala222Val) polymorphism of MTHFR, the 1595C-->G (Ser447Stop) polymorphism of LPL, and the -108/3G-->4G polymorphism of IPF1 were significantly associated with the prevalence of myocardial infarction. A stepwise forward selection procedure demonstrated that IPF1, MTHFR, and LPL genotypes significantly affected the prevalence of myocardial infarction. Combined genotype analysis of these polymorphisms yielded a maximum odds ratio of 2.54 for the combined genotype of TT for MTHFR, CC for LPL, and 3G3G for IPF1. The genotypes for MTHFR, LPL, and IPF1 may prove reliable for assessment of genetic risk for myocardial infarction. Determination of the combined genotype for these genes may contribute to primary, personalized prevention of this condition.


  • Open Access

    Evidence of a Cellular Protective Effect by Antecedent Angina Independent of Collateral Flow Recruitment During Coronary Angioplasty in Humans.

    by Hitoshi Matsuo, Sachiro Watanabe, Tomonori Segawa, Takeshi Hirose, Makoto Iwama, Shinichiro Tanaka, Takahiko Yamaki, Shuusaku Miyata, Tohru Kadosaki, Yukihiko Matsuno, et al.

    The main aim of this study was to elucidate whether the beneficial effect of antecedent angina is a cellular protective effect or the result of an increase of collateral flow. Of 42 patients with angina who underwent percutaneous transluminal coronary angioplasty (PTCA) for proximal left anterior descending artery (LAD) stenosis, 22 had experienced antecedent anginal pain (AP) within 7 days prior to PTCA. 99mTc-sestamibi was injected during balloon inflation, and quantitative analysis of ischemic severity during coronary occlusion was calculated (SS). An electrocardiogram was recorded during ballooning to calculate the sum of ST elevation (ΣST). ΣST was significantly reduced in patients with AP compared with patients without AP (1.88±0.89 mV vs 1.18±0.74 mV, p=0.0088); however, no difference was observed in defect severity. A close correlation was observed between SS and ΣST in both groups. The multivariate regression model demonstrated that both a large SS (pCirc J 2002; 66: 741 - 745)


  • Clinical significance of .ALPHA.-human atrial natriuretic peptide in patients on maintenance dialysis.

    by Hiroshige Ohashi, Hiroshi Oda, Yukihiko Matsuno, Sachiro Watanabe, Nobuyoshi Sugishita, Yasunori Kotoo, Katsumi Ueno, Akira Sugiyama, Kunihiro Okada, Tetsuo Matsubara, et al.

    心房性Na利尿ペプチド (α-hANP) の慢性血液透析 (HD) 患者と持続性自己管理腹膜透析 (CAPD) 患者の臨床的意義, とくにドライウエイトとの関係について検討した. 健常者10例 (男性5例, 女性5例, 平均年齢45.6歳), CAPD患者11例 (男性7例, 女性4例, 平均透析歴20.9か月), HD患者10例 (男性5例, 女性5例, 平均透析歴25.4か月) を対象とした. GAPDならびにHD患者の基礎疾患は全例, 慢性糸球体腎炎である. CAPD患者では心臓超音波検査施行日にα-hANPと限外濾過指数 (UFI) を測定した. HD患者ではHD前後に心臓超音波検査を, またHD前後ならびに次回HD前にα-hANPを測定した. また心エコー図法により左房径, 左室心筋重量を求めた. 以下の結論が得られた. 1. HD患者のα-hANPは健常者, CAPD患者に比較して上昇していた. 2. 左室心筋重量はCAPDとHD患者で増大していた. CAPD患者に比較してHD患者でその増大傾向は顕著であった. 3. 左房径とα-hANPとの間に有意の正相関が認められた. 4. HDによりα-hANPは減少した. α-hANPの減少率と体重減少率との間に有意の相関が認められた. 5. HD後と次回HD前のα-hANP増加率と体重増加率との間に有意な正相関が認められた. 6. UFIの低下しているCAPD患者のα-hANPは高値を示した. 以上よりα-hANPは慢性維持透析患者のドライウエイトの指標になり得るものと思われた. 具体的には, HD後ならびにCAPD中のα-hANP値が50ng/ml以下であればドライウエイトに到達している可能性が高いものと思われる.